CORRECTION – FDA Submission to Change the Primary Endpoint into an Industry First and Robust Clinical Measure for Superiority of CIN Phase 3 Study

by NASDAQ Market News April 29, 2020

NASDAQ Market News
Click here to email author

Conclusion of an Agreement in Principle Between Bold Capital and Dymedso, a Corporation Involved in Lung Disease Treatment and Treating COVID-19 Pulmonary Issues

I-Mab Filed 2019 Annual Report on Form 20-F

Ads